Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Identifieur interne : 000F95 ( Main/Exploration ); précédent : 000F94; suivant : 000F96Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
Auteurs : Jennifer L. Mckimm-Breschkin [Australie] ; Alicia M. Fry [États-Unis]Source :
- Antiviral research [ 1872-9096 ] ; 2016.
Descripteurs français
- KwdFr :
- Amantadine (usage thérapeutique), Antienzymes (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Facilitation dépendante des anticorps, Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Infections de l'appareil respiratoire (traitement médicamenteux), Infections de l'appareil respiratoire (virologie), Infections à Picornaviridae (traitement médicamenteux), Infections à coronavirus (traitement médicamenteux), Orthomyxoviridae (), Oséltamivir (usage thérapeutique), Rimantadine (usage thérapeutique), Réplication virale (), Résistance virale aux médicaments, Sialidase (usage thérapeutique), Syndrome respiratoire aigu sévère (traitement médicamenteux), Texas.
- MESH :
- administration et posologie : Antiviraux.
- effets indésirables : Antiviraux.
- pharmacologie : Antiviraux.
- traitement médicamenteux : Grippe humaine, Infections de l'appareil respiratoire, Infections à Picornaviridae, Infections à coronavirus, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Amantadine, Antienzymes, Antiviraux, Oséltamivir, Rimantadine, Sialidase.
- virologie : Grippe humaine, Infections de l'appareil respiratoire.
- Facilitation dépendante des anticorps, Humains, Orthomyxoviridae, Réplication virale, Résistance virale aux médicaments, Texas.
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Antibody-Dependent Enhancement, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Drug Resistance, Viral, Enzyme Inhibitors (therapeutic use), Humans, Influenza, Human (drug therapy), Influenza, Human (virology), Neuraminidase (therapeutic use), Orthomyxoviridae (drug effects), Oseltamivir (therapeutic use), Picornaviridae Infections (drug therapy), Respiratory Tract Infections (drug therapy), Respiratory Tract Infections (virology), Rimantadine (therapeutic use), Severe Acute Respiratory Syndrome (drug therapy), Texas, Virus Replication (drug effects).
- MESH :
- chemical , administration & dosage : Antiviral Agents.
- chemical , adverse effects : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- chemical , therapeutic use : Amantadine, Antiviral Agents, Enzyme Inhibitors, Neuraminidase, Oseltamivir, Rimantadine.
- drug effects : Orthomyxoviridae, Virus Replication.
- drug therapy : Coronavirus Infections, Influenza, Human, Picornaviridae Infections, Respiratory Tract Infections, Severe Acute Respiratory Syndrome.
- virology : Influenza, Human, Respiratory Tract Infections.
- Antibody-Dependent Enhancement, Drug Resistance, Viral, Humans, Texas.
Abstract
The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses.
DOI: 10.1016/j.antiviral.2016.01.012
PubMed: 26872862
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D03
- to stream PubMed, to step Curation: 000D03
- to stream PubMed, to step Checkpoint: 000C32
- to stream Ncbi, to step Merge: 002C00
- to stream Ncbi, to step Curation: 002C00
- to stream Ncbi, to step Checkpoint: 002C00
- to stream Main, to step Merge: 000F97
- to stream Main, to step Curation: 000F95
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.</title><author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name><affiliation wicri:level="1"><nlm:affiliation>CSIRO, 343 Royal Parade, Parkville, Australia. Electronic address: mck245@csiro.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO, 343 Royal Parade, Parkville</wicri:regionArea><wicri:noRegion>Parkville</wicri:noRegion></affiliation></author><author><name sortKey="Fry, Alicia M" sort="Fry, Alicia M" uniqKey="Fry A" first="Alicia M" last="Fry">Alicia M. Fry</name><affiliation wicri:level="2"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: agf1@cdc.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26872862</idno><idno type="pmid">26872862</idno><idno type="doi">10.1016/j.antiviral.2016.01.012</idno><idno type="wicri:Area/PubMed/Corpus">000D03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D03</idno><idno type="wicri:Area/PubMed/Curation">000D03</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D03</idno><idno type="wicri:Area/PubMed/Checkpoint">000C32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C32</idno><idno type="wicri:Area/Ncbi/Merge">002C00</idno><idno type="wicri:Area/Ncbi/Curation">002C00</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C00</idno><idno type="wicri:Area/Main/Merge">000F97</idno><idno type="wicri:Area/Main/Curation">000F95</idno><idno type="wicri:Area/Main/Exploration">000F95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.</title><author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name><affiliation wicri:level="1"><nlm:affiliation>CSIRO, 343 Royal Parade, Parkville, Australia. Electronic address: mck245@csiro.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>CSIRO, 343 Royal Parade, Parkville</wicri:regionArea><wicri:noRegion>Parkville</wicri:noRegion></affiliation></author><author><name sortKey="Fry, Alicia M" sort="Fry, Alicia M" uniqKey="Fry A" first="Alicia M" last="Fry">Alicia M. Fry</name><affiliation wicri:level="2"><nlm:affiliation>Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: agf1@cdc.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term><term>Antibody-Dependent Enhancement</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Resistance, Viral</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (virology)</term><term>Neuraminidase (therapeutic use)</term><term>Orthomyxoviridae (drug effects)</term><term>Oseltamivir (therapeutic use)</term><term>Picornaviridae Infections (drug therapy)</term><term>Respiratory Tract Infections (drug therapy)</term><term>Respiratory Tract Infections (virology)</term><term>Rimantadine (therapeutic use)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Texas</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amantadine (usage thérapeutique)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Facilitation dépendante des anticorps</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Infections de l'appareil respiratoire (traitement médicamenteux)</term><term>Infections de l'appareil respiratoire (virologie)</term><term>Infections à Picornaviridae (traitement médicamenteux)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Orthomyxoviridae ()</term><term>Oséltamivir (usage thérapeutique)</term><term>Rimantadine (usage thérapeutique)</term><term>Réplication virale ()</term><term>Résistance virale aux médicaments</term><term>Sialidase (usage thérapeutique)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Texas</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Neuraminidase</term><term>Oseltamivir</term><term>Rimantadine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Orthomyxoviridae</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Influenza, Human</term><term>Picornaviridae Infections</term><term>Respiratory Tract Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections de l'appareil respiratoire</term><term>Infections à Picornaviridae</term><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amantadine</term><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Rimantadine</term><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Infections de l'appareil respiratoire</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term><term>Respiratory Tract Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antibody-Dependent Enhancement</term><term>Drug Resistance, Viral</term><term>Humans</term><term>Texas</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facilitation dépendante des anticorps</term><term>Humains</term><term>Orthomyxoviridae</term><term>Réplication virale</term><term>Résistance virale aux médicaments</term><term>Texas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral Group Conference at the University of Texas on 2-4 June, 2015. With emerging resistance to the drugs currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase inhibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack of effective interventions against other respiratory viruses, the 3-day programme focused on the discovery and development of inhibitors of several virus targets and key host cell factors involved in virus replication or mediating the inflammatory response. Virus targets included the influenza haemagglutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza polymerases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential implications of antibody-dependent enhancement of disease were also addressed. Topics covered all aspects from structural and molecular biology to preclinical and clinical studies. The importance of suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both industry and government. This meeting summary provides an overview, not only for the conference participants, but also for those interested in the current status of antivirals for respiratory viruses. </div></front></TEI><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name></noRegion></country><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Fry, Alicia M" sort="Fry, Alicia M" uniqKey="Fry A" first="Alicia M" last="Fry">Alicia M. Fry</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26872862
|texte= Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26872862" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |